First of a new class of drugs for HIV

February 1996
Modern Medicine;Feb96, Vol. 64 Issue 2, p38
Reports on the United States Food and Drug Administration's approval of the drug Saquinavir mesylate (Invirase), indicated for HIV infections. Mode of action.


Related Articles

  • Pentafuside effective.  // AIDS Patient Care & STDs;Apr96, Vol. 10 Issue 2, p130 

    Reports on the effectiveness of pentafuside in preventing infection by HIV-1 in mice. Overview of the study on pentafuside performed in collaboration with US Food & Drug Administration; Mechanism of action.

  • Pentafuside shows anti-HIV activity.  // AIDS Patient Care & STDs;Jun96, Vol. 10 Issue 3, p184 

    Relates the results of a study conducted on the effect of pentafuside on HIV-infections in mice. Systemic effect of the drug; Ability of the drug to reduce the extent of HIV infection.

  • Resistance, remission, and qualitative differences in HIV chemotherapy. Kirschner, Denise E.; Webb, G.F. // Emerging Infectious Diseases;Jul-Sep97, Vol. 3 Issue 3, p273 

    Presents a design of a mathematical system that models human immunodeficiency virus (HIV) multidrug chemotherapy including uninfected and infected CD4+T cells and virus population. Inclusions in the model; Indications from the simulations; Important distinction between resistance and remission;...

  • First-line treatment of HIV infection.  // Modern Medicine;Nov96, Vol. 64 Issue 11, p33 

    Reports on the Food and Drug Administration's approval of Didanosine as a monotherapy for treating HIV infection when antiretroviral therapy is warranted.

  • Prescriptions pile up for AIDS combination therapy. Rodgers, Katie // Drug Topics;1/8/96, Vol. 140 Issue 1, p14 

    Reports on developments related to chemotherapy for advanced HIV infection. Includes the US Food & Drug Administration's approval of saquinavir protease inhibitor; Combination therapy with nucleoside analogs; Prescriptions for lamivudine.

  • High hopes. McCann, Jean // Drug Topics;Aug96, Vol. 140 Issue 15, p54 

    Reports that AIDS researchers are talking about turning HIV disease from an ultimately fatal infection into a chronic disease that can be controlled by chronic therapy. Findings on the effect of triple-drug therapy on HIV; Comparison of HIV infection to a raging fire; Treatment of patients with...

  • Dosing guidelines for foscarnet and trimetrexate.  // Formulary;Jun95, Vol. 30 Issue 6, p349 

    Presents dosing and monitoring guidelines for foscarnet sodium and trimetrexate glucuronate used to treat patients with opportunistic infections associated with HIV infection. Guidelines by the P & T Committee at the Trinity Lutheran Hospital in Kansas City, Missouri; Discussion of drugs;...

  • Clinical efficacy of monotherapy with stavudine compared with zidovudine in HIV-infected... Spruance, Spotswood L.; Pavia, Andrew T. // Annals of Internal Medicine;03/01/97, Vol. 126 Issue 5, p355 

    Evaluates the clinical effect of stavudine monotherapy in HIV positive persons. Comparison of the effectiveness of the drug with zidovudine; Rate of clinical progression in patients receiving the drug; Resolution of neuropathy in patients receiving the drug; Toleration of patients to the drug;...

  • Crushing HIV. Richardson, Sarah // Discover;Jan97, Vol. 18 Issue 1, p28 

    Reports on advances in chemotherapy against HIV infection. Mult-drug regimen; Protease inhibitors; Cost considerations; Side effects of the drug; Chances of complete remission.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics